pleas refer disclosur appendix analyst certif import disclosur price chart disclosur specif cover
compani statement valuat risk avail
llc member svb group
overview
valuat risk
merck invest thesi valuat risk
initi coverag outperform rate price target
mrk fortun tie keytruda sale trial readout primari driver share price
mrk earli all-in bet solid clinic commerci execut establish deep competit platform-moat
believ investor underappreci potenti
long-term divers keytruda revenu come expans earlier line addit tumor type
 return mrk aggress strategi explor collabor pursu partnership acquisit promis
keytruda add-on approach extend keytruda competit moat life-cycle beyond patent-lif
flip side believ investor overli worri price disrupt view exceedingli
expect continu growth vaccin gardasil pediatr vaccin long-term prospect stabl given high barrier
brand gener entri
mrk pipelin asset see potenti disrupt islatravir hiv extend dose prep well
opportun show industry-lead market-shap gefapix chronic cough
project revenu gener rang outcom keytruda mrk io asset deriv mont
carlo simul entir io industri pipelin develop path iter model growth vaccin
hiv franchis consensu estim vertic
price target base dcf use wacc account net cash
keytruda franchis
increment scientif innov io may continu prove difficult initi burst
fail pursu most-promis add-on therapi bd competitor reli deeper intern pipelin
price reimburs
us legisl affect drug price propos price model risk commerci pharma keytruda
exposur medicar part could make particularli sensit
us health-system reform oncolog model remov practic incent prefer high-volum high-reb option
major leg keytruda competit moat
risk reimburs enhanc oversea re-negoti drug switch routin practic low-cost
local altern china could drive price one keytruda fastest grow market
found
eq
merck one world largest
pharmaceut compani global
footprint broad product offer divers
mrk shift primari care oncolog
like acceler come year continu
keytruda expans loe januvia
data catalyst remain
data keytruda neoadjuv chemo
data keytruda non muscle-invas
therapi tnbc
bladder cancer nmibc unrespons bcg
data keytruda w/ chemo tnbc
data msi-h/dmmr colorect cancer
data keytruda w/out chemo bladder
data keytruda w/ plat chemo sclc
data gefapix endometriosis-rel pain
data keytruda cutan squamou
aug loe loss exclus
mid- late-stag pipelin overview
cavatak oncolyt viru keytruda
keytruda adj cscc
lenvima keytruda
r/r mss colorect cancer
keytruda neoadj /adj bc
neoadj /adj tnbc
lynparza incl keytruda
inhibitor
lenvima keytruda r/r tnbc
ovarian gastric mss gbm
vaccin cytomegaloviru
anti- rsv mab
keytruda msi-h colorect cancer
keytruda lynparza mainten
keytruda chemo-nav
keytruda mesothelioma
conjug vaccin
selumetinib mek inhibitor
keytruda nasopharyng cancer
gefapix receptor antagonist
islatravir infect
keytruda lynparza ovarian
vericiguat sgc stimul heart failur
undisclos moa
lenvima keytruda unfit urotheli
pipelin overview juli
exclud certain line
extens new formul
lenvima keytruda melanoma
ebola
lenvima keytruda endometri
lynparza mainten gbrca-
lenvima keytruda
merck valuat ratio higher end peer group justifi stronger
note differ busi group contain within make cross-comparison mislead valuat ratio would higher anim health busi strip
profit margin vs pharmaceut segment
svb leerink factset financi aug
absent major acquisit expect becom increasingli
depend keytruda revenu primari care declin import
io sale
oncolog
anim health servic
continu growth
gardasil plu contribut
new product primari care
pipelin fail compens
sale percent
total revenu rise
svb leerink estim share top-line sale use product partner profit share arrang estim assum major divestur acquisit
estim oncolog grow nearli half sale though
franchis reach abbv-humira level depend revenu
project sale ww total
shift rel revenu contribut primari
care oncolog
compani report svb leerink estim estim assum major divestur acquisit
share keytruda revenu move step major
success w/ chemo nonsq
nsclc nsclc
success
nsclc opdivo fail
nsclc
applic
opdivo yervoy
advanc nsclc
opdivo fail
sclc
success w/
inlyta rcc
arm fail
nsclc
success strategi execut nsclc enabl keytruda
overtak opdivo share adopt cpi slow
quarterli global sale class
simul predict continu growth keytruda mid- long-term
base volum price
estim keytruda sale us
simul develop path iter bn per quarter
percentil
percentil
street view mid-term keytruda perform risen sharpli
past two year addit trial read posit
global keytruda sale consensu
svb leerink ionian simul visibl alpha aug
long-term oncolog out-performance drive differenti view
ww
expans
posit
outlook gardasil
oncolog
simul success addit io
candid broader use non-io oncolog
asset combin keytruda via ionian
rather level see growth acceler
simul develop path iter bn
base success
earlier line longer
durat treatment
chemotherapi
own
acquir futur year
post-lo
expect abl
combin co-
formul
loe loss exclus
svb leerink ionian simul consensu visibl alpha aug
near-term data catalyst keytruda impact
impact
unrespons
could support acceler approv on-going
keytruda bcg recurr nmibc
serv confirmatori
expect regist data
packag recent initi adjuv
plat
annual patient opportun base
success previous untreat metastat
urotheli cancer elig platinum
chemotherapi
annual patient opportun previous
annual patient opportun prev
annual patient opportun chemo-nav
tnbc assum success
china nrdl nation reimburs list drug
patient fall nrdl-list indic
compani report clinicaltri gov discuss
mileston event competitor implic
cancer set impact market dynam tumor set
data
inform go no-go decis start
result would read-through
os benefit detail expect investor
compar cross trial
data
expect success could provid addl
evid relev tmb biomark
primari os btmb
data
expect low result posit
differenti roch shown
impow trial tecentriq
data
data
full data
expect given lack treme success to-
date though opdivo yervoy posit signal
success would differenti
/- chemo
near-term label popul
os primari imfinzi monotherapi vs chemo low
expect data competit kn-
result keytruda plu chemo
investor compar cross-trial
tecentriq chemo mo
data catalyst approv
keytruda w/ plat chemo
data opdivo yervoy chemo
data opdivo cabozantinib
data
data opdivo yervoy
near-term catalyst key program outsid io
present
keytruda path
built impress keytruda franchis
near-term data-packag support lead competit posit largest io indic nsclc
melanoma rcc gastroesophag scchn
continu indic expans single-ag chemotherapi combin includ adjuv
set potenti longer duration-of-therapi new launch possibl
long-term diversif sale reduc depend nsclc
industry-lead clinic strategi trial execut capabl
deepest platform-moat ever biopharma protect keytruda competit
shape convers built signific physician experi loyalti first anti-
market eight tumor type half tumor cpi approv
reput lead succeed competitor fail nsclc
highest number total uniqu indicationseveri practic must stock keytruda
volum volume-bas discount creat financi rebat wall practic
financi practic like better use keytruda low-pric entrant even free
uniqu mechanist combin trial keytruda bd commit
execut abil pursu promis add-on approach ensur keytruda option
alway avail extend life-cycle keytruda beyond patent-lif
massiv network academ industri collabor
percept interchang increas physician use preferred-anti-
regardless compani pursu label
see risk long-term domin horizon
risk keytruda sale growth franchis domin
competitor manag launch nsclc near-term base single-ag
chemotherapi combin trial read-out next year
return develop declin increment scientif innov io continu prove
difficult initi burst
re-negoti european hta driven keytruda price new launch especi
low-cost altern china drive price one keytruda fastest grow market
keytruda exposur medicar part could make particularli sensit us price
us health-system reform oncolog model remov practic incent prefer high-
volum high-reb option major leg keytruda competit moat
opdivo tecentriq dead
io biolog difficult risk-hedg across mechan may win end mrk
closest competitor novel io-asset
mrk strategi wide collabor academia industri could fail collabor
choos regist combin competitor
rhhbi close behind build moat opdivo tecentriq rhhbi
also leverag relationship contract across oncolog bag
percept interchang increas physician use preferred-anti-
regardless compani pursu label
keytruda rapid adopt track mrk aggress
keytruda sale trial start approv histori
bladder r/r
bladder unfit
continu make substanti progress keytruda label-expans
compar competitor
statu us
svb leerink text monotherapi combin drug agent refer threshold
success adjuv neoadjuv set open opportun
larger indic keytruda
clinicaltri gov approxim present diagnosi seer
still see signific growth opportun remain label expans
earlier line addit tumor type
address patient opportun keytruda us
given on-going develop expect expand keytruda
label diversifi sale
ionian simul keytruda sale us
percent indic total
ionian simul keytruda sale us
percent indic total
consensu assum tumor mix keytruda remain stabl
ionian reveal signific growth potenti overlook indic
keytruda share sale us tumor
keytruda share sale us tumor
tumor includ breast pancreat cancer
increas ionian project keytruda us sale
simul develop path iter bn tumor set
eros keytruda
domin nsclc
novel
opportun keytruda
data i-spi show
addit keytruda tripl
pcr tnbc vs
doubl
pcr bc
vs recent success
similar immunolog believ use scale build moat
keytruda franchis oncolog opdivo
number fda-approv indic
moat strength
shape convers
comprehens uniqu indic
volume-bas contract payer
number fda-approv indic
number uniqu mechanist combo
sourc moat strength
shape convers
inhibitor includ fda-approv indic tumor type biomark line august exclud libtayo
near-term believ keytruda opdivo continu
domin class
probabl near-term us revenu
percent simul develop path mont carlo iter
revenu bn
addit tumor type expans occur slowli part
combin given tumor without approv less immunogen
keytruda approv tumor type
like first approv single-ag combin tumor type
tumor immunogen score combin tmb percent patient mut/mb viru associ medacorp kol survey
return develop declin increment scientif innov
prove difficult initi burst
keytruda posreg poc yield
opdivo posreg poc yield
tecentriq posreg poc yield
imfinzi posreg poc yield
registr trial yield calcul divid posreg trial trial could support registr initi poc proof-of-concept trial start two year prior
show sharp declin compani move harder shot goal
higher attrit novel io combin reduc probabl upsid
revenu keytruda averag long-term revenu fall
probabl keytruda us revenu
percent simul develop path mont carlo iter
revenu bn
revenu bn
program target everi step cancer immun cycl
bold wholli own
addit pipelin relev io
undisclos moa bispecif
addit io
mechan investor day
yet know specif detail
program
expect keytruda retain lead competitor could
overtak leadership given extens hedg novel io-asset
probabl keytruda us revenu
percent simul develop path mont carlo iter
revenu bn
much mrk combin shots-on-go collabor
see annual long-term us sale risk fail secur
keytruda posit promis combin
probabl keytruda us revenu
percent simul develop path mont carlo iter
revenu bn
revenu bn
collabor keep keytruda promis
lose keytruda posit promis
registr trial
said shown readi engag high-valu collabor
secur asset could extend keytruda reach
keytruda lead statu led strong industri academ interest test keytruda novel set
novel combin industry-lead strategi freeli share drug believ studi
expect aggreg industry-lead databas io activ biomark data enabl
flexibl guid busi develop activ collabor competitor
partner astrazeneca lynparza follow earli clinic data indic synergi
cpi parp inhibitor
partner eisai lenvima vegfr tki combin show efficaci multipl
complet acquisit viralyt oncolyt viru program cavatak
program
lynparza olaparib
selumetinib astrazeneca
lenvima lenvatinib eisai
laherparepvec amgen
nsclc
up-front
up-front
small recent deal support keytruda franchis
cash mileston
fl combin
radiat keytruda
next-gen gener
intratumor administr
zvex vector preclin stage
program design gener
cytotox t-cell effector cell
vivo infiltr tumor make
inhibitor
r/r metastat clear cell rcc von
inhibitor
preclin develop non-
oncogen driver rcc
potenti improv
safety/efficaci profil rel
avail vegfr tki extend
mrk commerci reach rcc
r/r pr
orr
patient express
potenti predict biomark
high express
shrinkag uninject tumor
preclin antibodi target latent
tgf precursor complex could
avoid toxic
observ small molecul inhibit
matur activ form tgf
tgf pleiotrop non-
tumor suppress cytotox
macrophag dc ii
promot
treg iii stroma exclud
t-cell tme
promis mechan
kol survey measur
alloc invest
decreas tgf secret vitro
inhibit tumor growth multipl
import busi develop deal keytruda franchis includ acquisit rigontec agonist partnership mrna neo-antigen vaccin
expect continu growth compound-annual-growth-rate vaccin
stabl long-term prospect given high barrier brand gener entri
expect growth vaccin broader adopt gardasil
pediatr vaccin
dynam commerci vaccin franchis
recommend male femal age prevent common type hpv type
provid protect cervic cancer
hpv vaccin avail domest sinc gsk pull cervarix us market
opportun signific elig popul receiv hpv vaccin
pediatr combo vaccin proquad/mmrii/varivaxgrowth outbreak
measl mump rubella chickenpox
recent measl outbreak drive growth pediatr adult re-vaccin
merck measl vaccin supplier us
hexaval diphtheria tetanu pertussi poliomyel hepat invas diseas due
haemophilu influenza type vaccin jointli develop sanofi
expect sale reach recent approv us expect avail
shingl elderli
expect revenu larg disappear competit shingrix gsk efficaci
broader label
prevent pneumococc diseas children
adult compet prevnar juggernaut
btd compet btd pneumococc conjug
candid replac current offer prevnar pneumovax merck
pneumovax recommend adult sale us
prevnar sale us recommend children
adult may see declin given us aicp recommendation-downgrad adult june
support discern impact measur outcom given herd
immun provid broad pediatr vaccin
also develop altern construct target serotyp unaddress
pediatr formul relev adult infect
biolog
conjug vaccin contain polysaccharid
serotyp also contain prevnar two addit serotyp
highli preval infant infect studi trial includ two
adult four pediatr popul five immunocompromised/high risk popul
contain seven addit serotyp prevnar includ yet
report clinic data infant three trial on-going adult
trial design set data gener
random trial
compar prevnar
infant age
immun respons non-
inferior prevnar across share
serotyp immun respons
threshold observ
infant
rate sae
compar
late multipl readout
anticip approv
medacorp kol interview european societi paediatr infecti diseas
note btd fda breakthrough design aicp advisori committe immun practic
expect promis hiv pipelin compens specialti asset loe
estimate biggest declin next decad
estimate biggest gainer next decad
hiv lose share
biosimilar seiz
major eu sale
first- best-in-class
declin
label extens expect
insomnia alzheim
like use last resort
compani report svb leerink estim note loe loss exclus consensu estim use non-hiv drug visibl alpha
islatravir hiv could disrupt market extend
dose prep
islatravir novel-mechan investig therapi evalu treatment
pre-exposur prophylaxi prep excit potenti less-frequ
administr improv complianc physician confid prescript patient
long intracellular half-lif data indic singl oral dose suppress hiv
replic least week infect patient
subderm implant formul reveal favor pk data potenti once-
yearli option prep vs once-daili current standard
islatravir nucleosid revers transcriptas transloc inhibitor nrtti inhibit hiv
multipl mechan immedi delay chain termin
vitro data show potent activ strain includ multi-drug resist strain
trial design set
oral islatravir art
replic least seven day
rapid robust reduct viral load
observ vl declin
baselin dose test
dose well toler
limit number mild/moder
report
sae discontinu due
islatravir
healthi volunt
intracellular concentr pbmc
pk threshold
week project remain
threshold month
red indur mild
moder sever
discontinu due
sept start random assess once-
monthli oral islatravir prep
come loe januvia franchis type ii diabet
acceler mrk transit away low-margin primari care product
januvia sitagliptin lose patent protect us eu japan combin sale
januvia janumet fix combin sitagliptin metformin expect rapidli declin
loe
steglatro ertugliflozin sodium glucos co-transport inhibitor approv late type-
diabet expect blockbust fourth class yet demonstr
cardiovascular benefit like competitor jardianc invokana
number promis primari care asset pipelin specif gefapix vericiguat
risk-adjust expect combin sale program replac januvia janumet declin
compani report svb leerink note loe loss exclus consensu estim visibl alpha
gefapix chronic cough could tip
iceberg applic sensori autonom disord
gefapix chronic cough endometriosis-rel pain
highli efficaci reduc cough frequenc major patient also report
tast perturb like off-target inhibit discontinu low
larg potenti chronic cough requir compet large-pharma commerci
support diseas awar excit asset merck hand
histor excel market shape fosamax
select antagonist earlier develop shown similar level
efficaci anim model gefapix better toler
oral small molecul antagon receptor express sensori
autonom neuron play key role trigger cough reflex mechan could also
applic sensori autonom disord
trial design set
random studi
bid gefapix
awak cough frequenc
baselin estim
placebo
experienc loss
alter tast
character
random studi
bid gefapix
complet
random studi
bid gefapix
enrol trial complet
top-line data trial
top-line data trial
clinicaltri gov note merck gain gefapix acquisit privat held affer up-front mileston consensu estim visibl alpha
page updat post-publ correct mistak clinic data section well add clarifi languag
vericiguat heart failur face consider market risk
higher-than-typ clinic risk
vericiguat oral solubl guanyl cyclas sgc stimul placebo-control
trial patient heart failur reduc eject fraction hfref
primari endpoint victoria trial clinic composite-endpoint time
first occurr cardiovascular death hf hospit dose titrat
vericiguat fail achiev signific reduct nt-probe biomark
heart failur patient worsen hfref although benefit clinic
composit endpoint dose-respons greatest highest dose
impact mortal observ across five trial vericiguat riociguat
heart failur patient although qualiti life improv
even approv slow uptak entresto novarti highlight reimburs challeng
novel therapi larg primari care indic like heart failur
merck gain us right vericiguat bayer part deal also receiv
ex-u right adempa riociguat approv sgc stimul pulmonari hypertens
trial design set
rate composit cv death
hf hospit
placebo
rate sae highest
placebo group rate ae
studi discontinu
similar vericiguat
top-line data victoria trial
medicin baltimor jama benefit decreas hf hospit subject endpoint often predict global
outcom across divers healthcar system consensu estim visibl alpha
like mani big pharma larg number legaci program
slow declin aggreg contribut signific revenu
global diversifi franchis revenu
drug sale
note diversifi brand includ sever former blockbust drug steadili declin sale gener competitor captur greater share drug sale
drug merck break discret salescombin sale
anim health growth busi diversifi mrk revenu base
sale anim group last year
repres total revenu
divis mrk workforc
task prevent treat control
diseas livestock companion anim
highest intern exposur
signific region differ sale
major us sale pet product
compound-annual-growth-rate mrk anim health group averag
recent year mid-singl digit growth seen
trend drive growth includ rise incom increas
urban world-wide fuel pet ownership greater
profit anim health synergi rest support
inclus
divis oper near profit margin
recent year account cost sale sg
 directli incur
compar favor calcul oper margin
elanco zoeti recent spun
pharmaceut compani lilli elanco
expect disrupt group current
statu unit strong top- bottom-lin growth
mrk continu belief keep unit in-
hous allow realiz cost
synergi mrk strong financi posit
 collabor common area
endocrinolog enter respiratori
greater spend pet also enabl
applic research emerg
indic like oncolog pain
potenti stand-alon valu anim health svbl estimate
report segment profit apples-to-appl sinc gener support mrl account compani report svb leerink
shift away primari care keytruda expans drive expect
sg sale declin time reach roch pharma level
histor estim total revenu sg sale
note loe loss exclus
histori reliabl dividend mrk capit alloc strategi
balanc invest growth sharehold incom
histor estim use net oper cash flow
consist guid target pay-out ratio growth forecast support doubl dividend
come decad
capital-expenditure guid rise total period increas spent
period even increas still gener signific excess capit
near-term could redirect busi develop share repurchas
even though leverag ratio highest theyv recent histori
mrk debt profil remain healthi credit rate near high qualiti grade
although signal large-scal consider balanc sheet loan
capac provid option expect opportunist time manag
describ sector target rich environ term financi scientif valu overlap
tickersvb leerink ratingsvb leerink highmarket cap cash/sharecash equiv ev manag
frazier departur horizon successor like come
within dont expect signific shift strategi transit
although mrk board elimin mandatori retir age frazier reach year-end
retir loom given mrk histori promot intern candid ceo role
replac like anoth member c-suit
see clyburn lead contend consid longev firm leadership role across
multipl busi unit recent global oncolog oversaw keytruda launch rise
approach mont carlo simul entir immuno-
risk dynam consid
probabl technic
probabl disrupt outcom
correl outcom everi
treatment mechanist class
develop path poc trial
probabl mont carlo simul
probabl technic
note use discount rate compani given simul revenu stream alreadi consid mani risk typic account higher discount rate
